Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Never Stop Looking – Making a Genetic Diagnosis of Cystic Fibrosis in an Adult Patient With Bronchiectasis
Reddy, Alyssa , Aksamit, T.R., Chalmers, Sarah , Nanda, S. , Kalscheur, C., Pichurin, Pavel N. , Joshi, Avni Y. , Reddy, A., Iyer, Vivek

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4131-A4131

10.1164/ajrccm.2025.211.abstracts.a4131 Get It

Abstract Introduction: Cystic fibrosis (CF) is a genetic disorder characterized by defective chloride ion transport, leading to thick mucus production, chronic respiratory infections, and other multisystem involvement. Although CF is often diagnosed in childhood, the condition can be missed or misdiagnosed in adults. Description of Case: We present the case of a 60-year-old male from India who was diagnosed with CF after a prolonged period of sinopulmonary symptoms. He initially presented in 2014. His medical history was pertinent for asthma, and multiple episodes of clinically and radiographically confirmed pneumonia and polypoid sinusitis requiring IV antibiotics and sinus surgery. He carried a prior diagnosis of allergic bronchopulmonary aspergillosis treated with itraconazole and steroids, as well as elevated IgE levels. His CT chest was notable for extensive bronchiectasis, bronchial wall thickening, and mucus plugging of both lungs. He had no known family history of CF. Sweat chloride testing was in the intermediate range (44, 47 mmol/L; normal <30 mmol/L, intermediate 30 to 59 mmol/L, abnormal >59 mmol/L). Given high suspicion for CF, cystic fibrosis transmembrane conductance regulator (CFTR) full gene analysis was pursued. Sequence analysis and multiplex ligation-dependent probe amplification of the CFTR gene detected heterozygous sequence changes c.1717-2A>T, classified as likely deleterious, and c.1367T>C (p.V456A), variant of uncertain significance. He was thus initially diagnosed as a CF carrier. He re-presented in 2024 with decline in pulmonary function testing and continued sinopulmonary infections. Genetic testing results from 2014 were re-analyzed. Between initial presentation and present, his V456A variant was upgraded to pathogenic. He met diagnostic criteria for CF with two pathogenic CFTR variants, a repeated intermediate sweat chloride (47 mmol/L) suggestive of CFTR protein dysfunction, and disease that could be attributed to CFTR dysfunction. He subsequently started TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) and airway clearance therapy. Discussion: The diagnosis of CF in adults can be challenging, particularly in individuals without a known family history, intermediate sweat chloride testing, and with inconclusive genetic testing. Our understanding of CF in Asian populations is limited. CF is suspected to be underreported in patients with Southeast Asian ancestry in part due to genetic heterogeneity. The interpretation of certain genetic variants can evolve over time. A variant of unknown significance may later be reclassified as pathogenic, revealing its true role in disease development. This highlights the critical importance of regularly re-evaluating genetic test results.
Incidence of Eosinophilic Inflammation in Bronchiectasis Varies Significantly With Blood Eosinophil Count Assessment Strategy
Alitelat, Alwatheq , Labban, M. El, Doumat, Georgina , Chalmers, Sarah , Aksamit, T.R., Kanj, Amjad

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3466-A3466

10.1164/ajrccm.2025.211.abstracts.a3466 Get It

Abstract RATIONALE: Absolute Blood Eosinophil Counts (BEC) in bronchiectasis patients offer insights into inflammatory patterns and potential treatments. In non-cystic fibrosis bronchiectasis (NCFB), BEC≥300 cells/μL characterizes Eosinophilic Bronchiectasis (EB), a type-2 inflammation endotype estimated in 20% of patients. Guidance on BEC assessment strategy (i.e., number, frequency and timing of BEC≥300 defining this endotype) is unclear. We hypothesize that EB incidence varies by BEC≥300 assessment strategy. We also investigate eosinophilic inflammation in CF for comparison. Objectives: Assess BEC≥300 incidence in NCFB and CF cohorts. METHODS: From January 2023 to October 2024, BEC were measured in 9,953 stable bronchiectasis patients across Mayo Clinic, including 9,806 with NCFB (J47.9; 66,780 CBCs) and 147 with CF (E84.0; 1,405 CBCs). Incidence of BEC≥300 was evaluated in relation to CBC frequency and timing (i.e., BEC≥300 on first, second, last, any, any two, first two simultaneously) and the number of CBCs per patient. RESULTS: In the NCFB cohort, median age was 74 years (IQR:66-82), with 59.5% female. Median CBCs/patient was 3 (IQR:1-7). Incidence of BEC≥300 on the first CBC was 19.8%. Among patients with ≥2 CBCs (n=7,075), incidence was 20.1% on the first, 19.8% on the second, and 20.0% on the last. This incidence rose to 36.3% when considering any CBC/patient. BEC≥300 on at least two CBCs was 29.3%, decreasing to 11.8% when considering consecutive BEC≥300 on both first and second CBCs. The incidence of BEC≥300 increased linearly with the number of CBCs obtained: 24.6% for those with 1-3 CBCs, up to 64.6% for >12 CBCs. In the CF cohort, median age was 36 years (IQR:27-52), with 55.1% female. Median CBCs/patient was 4 (IQR:2-8). BEC≥300 was present in 22.9% of first CBCs, rising to 36.3% when considering any CBC and 29.3% when present on at least two CBCs. Similar to the NCFB cohort, incidence increased with the number of CBCs: 26.5% for 1-3, up to 77.3% for >12. CONCLUSIONS: The incidence of BEC≥300 in our NCFB cohort remained steady at 20% at any specific measurement point, consistent with prospective literature. However, nearly half of those with BEC≥300 on the first or second CBC did not meet this threshold on both. Incidence significantly increased when any CBC was considered, and more CBCs were available. Similar observations were made in the CF cohort. Clearer BEC assessment strategies are needed to define clinically significant eosinophilic inflammation in bronchiectasis, to better identify patients who may most benefit from type 2 inflammation-targeted treatments.
Frailty is Associated With Increased Risk of 30-day Readmission After Bronchiectasis Exacerbation
Labban, M. El, Alitelat, Alwatheq , Chalmers, Sarah , Kanj, Amjad

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1991-A1991

10.1164/ajrccm.2025.211.abstracts.a1991 Get It

Abstract Purpose: Frail and malnourished patients with bronchiectasis have worse outcomes. This study examines frailty and malnutrition as predictors of 30-day readmission after bronchiectasis exacerbation (BE). Methods: We utilized the 2018 Nationwide Readmissions Database to analyze hospitalizations for BE. Patients with BE were identified through principal and secondary ICD-10 diagnosis codes J47.0 and J47.1. Among those who survived the index hospitalization, only individuals discharged to home were included in the analysis. The primary objective was to identify predictors of 30-day readmission, with a specific focus on frailty and malnutrition. Frailty was measured using the validated Hospital Frailty Risk Score, as described by Gilbert et al. (Lancet, 2018), while malnutrition was identified using ICD-10 codes E43, E44.0, E44.1, and E46. Comorbidity burden was categorized using the Charlson Comorbidity Index: mild (score 0-2), moderate (3-5), and severe (≥6). A multivariate logistic regression model was employed to calculate adjusted odds ratios (ORs) for readmission, with statistical significance defined as p < 0.05. Results: Among 20,742 patients discharged home following bronchiectasis exacerbation, 4% (830) were readmitted within 30 days. Patients with readmission were younger (median age 63 vs. 69 years, p<0.01) and more likely to be treated at urban hospitals (84.9% vs. 80.0%, p=0.01). They also had higher rates of frailty (52.6% vs. 46.5%, p=0.01), malnutrition (21.0% vs. 14.7%, p<0.01), and Pseudomonas pneumonia (5.9% vs. 3.9%, p=0.03). The comorbidity burden was not different (p=0.29). After adjusting for age, malnutrition demonstrated a trend toward higher odds of readmission (OR 1.31, 95% CI 0.99-1.73, p=0.059), though this did not reach statistical significance. In contrast, frailty was significantly associated with increased readmission (OR 1.36, 95% CI 1.12-1.66). The presented Table describes the demographic characteristics and outcomes of ALL hospitalized patients with BE (n = 40, 789) stratified by frailty and malnutrition. Conclusions: Frailty is a significant predictor of 30-day readmission following BE. Targeted interventions addressing frailty in hospitalized patients with BE may help reduce readmission rates.
Dipnech: Clinical Characteristics of an International Case Series
O'Brien, H., O’Callaghan, Michael , Penugonda, M., Almeamar, Hussein , Samhouri, Bilal F. , Veltkamp, Marcel , Manali, Effrosyni D. , Lazaratou, A., Papiris, Spiridon, Carr, Laurie, Kolilekas, Lykourgos , Daniil, Z., Hernández‐González, Fernanda , Torres, J. Sellares, O’Shea, Diarmuid , Murphy, D.J., Fabre, Aurélie , Forde, Sarah H. , Diesler, Rémi , Ryu, Jay H. , Bonella, Francesco , Cottin, Vincent , Taillé, Camille , McCormack, Francis X. , Gupta, Nishant , Strosberg, Jonathan , Lococo, Filippo , Harari, Sergio , Bouros, Demosthenes , Dimeas, Ilias E. , Torres, J. Sellares, Spagnolo, Paolo , Franciosi, Alessandro N. , Crowley, Rachel Katherine , O’Toole, Dermot , Byrne, Adam J. , Keane, Michael P. , Fournel, Ludovic , McCarthy, Cormac

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1804-A1804

10.1164/ajrccm.2025.211.abstracts.a1804 Get It

Abstract Rationale: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a pulmonary condition characterised by neuroendocrine cell proliferation along respiratory bronchioles resulting in tumourlet formation which may progress to pulmonary carcinoid. DIPNECH is a rare and under-recognised condition that predominantly affects females, with an estimated worldwide incidence of 5-6 people per million population. Given it's rarity and the poor understanding around the pathogenesis and treatment of this condition, we undertook the largest international case series to date of DIPNECH patients. We aim to further characterise this patient cohort to better understand the clinical features, identify common pulmonary function test (PFT) patterns and radiographic findings and describe current treatment practices. Methods: We collated data from 17 centres across 8 different countries comprising a total of 258 patients. Data collected included patient demographics, smoking history, symptoms, co-morbidities, pathological diagnosis, imaging findings, PFT pattern and therapies. Results: In total 258 patients were identified. The median age was 65 (SD+/- 10.6). 241 (93%) were female. 39% (n= 94/243) were ex-smokers. 79% (n=186/234) of patients reported pulmonary symptoms with cough being the most common symptom reported in 81% (n=151/186) of patients. Many patients were polysymptomatic, with cough and dyspnoea being the most common combination of symptoms described. (50.54%; n=94/186). Complete spirometry pattern was documented for 180 patients (69.78%) with an obstructive pattern being the most commonly observed (n=76/180; 42%). 27.5% (n=41/139) had clinically significant FEV1 reversibility post bronchodilator administration. Pathology specimens were available in 219 cases. Most common pathological features were neuroendocrine hyperplasia which was observed in 75% (n=165/219) and tumourlets in 74% (n=162/219) of cases. Carcinoid, either typical or atypical, was observed in 64% (n=141/219) of samples. 252 patients had computed tomography (CT) imaging performed. Pulmonary nodules were the most common feature identified in 99.60% of cases (248/250). Mosaic attenuation (69.30%; n=50/173) and airway dilatation (28.90%; n=50/173) were also frequently reported. There was no significant correlation between symptoms (cough, dyspnoea, wheeze) and airway dilatation (p=0.496), mosaic attenuation (p=0.496) and PFT pattern (p=0.837). There was a significant association between presence of symptoms and mosaic attenuation on CT (p=0.003). Conclusions: DIPNECH, while a rare disorder, is understudied. This international case series is the largest performed to date and highlights the complexity in management of these patients.
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Perez, Kimberly , Rivero, Jaydira Del , Kennedy, Erin B. , Basu, Sandip , Chauhan, Aman , Connolly, Heidi M. , Dasari, Arvind , Gangi, Alexandra , Clarke, Callisia N. , Hallet, Julie , Grady, Erin , Ivanidze, Jana , Mittra, Erik , White, Sarah B. , Raj, Nitya , Vijayvergia, Namrata , Lewis, Mark A. , Kunz, Pamela L. , Mailman, Josh , Arshad, Junaid , Singh, Simron , Chandrasekharan, Chandrika, Janson, Eva Tiensuu , Bergsland, Emily K. , Del Rivero, Jaydira , Dasari, Arvind N , Howe, James R , Grady, Erin , Ivanidze, Jana , Raj, Nitya , Vijayvergia, Namrata , Kunz, Pamela L , Mailman, Josh , Arshad, Junaid , Soares, Heloisa P , Singh, Simron , Soulen, Michael C , Halfdanarson, Thorvardur R , Strosberg, Jonathan R , Clarke, Callisia N , Howe, James R. , Chan, Jennifer Ai-wen , Soares, Heloisa P. , Hálfdánarson, Þorvarður R. , Strosberg, Jonathan

Mayo Clinic

JCO Oncology Practice | May 9, 2025 | Volume: 22 | Issue: 1 | Pages: 19-35

10.1200/op-25-00133 | PMID 40344544 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more. PURPOSE To develop a clinical practice guideline and recommendations for symptom management of patients with well-differentiated grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors. METHODS ASCO convened an Expert Panel to develop a clinical practice guideline by reviewing the literature for relevant guidelines, systematic reviews, randomized controlled trials (RCTs), and observational studies to develop recommendations for clinical practice. RESULTS The literature review identified eight guidelines, 19 systematic reviews, and three RCTs that informed the development of guideline recommendations. RECOMMENDATIONS Recommendations are included for carcinoid syndrome, carcinoid heart disease and carcinoid crisis, and functional pancreatic neuroendocrine tumor syndromes. Recommendations are provided for surgical management, liver-directed therapy, and systemic therapy options, as well as palliative care. Limited guidance is provided for sequencing of interventions. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Endovascular rodent model using tail access and ultrasound guidance
Ognard, Julien , Hajj, G El , Lortscher, Sarah, Bayraktar, Esref Alperen , Brinjikji, Waleed , Kadirvel, Ramanathan , Kallmes, David F. , El Hajj, Gerard , Bayraktar, Esref Alperen , Oliver, Alexander A , Brinjikji, Waleed , Kadirvel, Ram , Ognard, Julien , Ding, Yonghong

Mayo Clinic

Journal of NeuroInterventional Surgery | May 9, 2025 | Volume: 18 | Issue: 5 | Pages: 1487-1487

10.1136/jnis-2025-023444 | PMID 40345800 Get It

We have developed a cost-effective method to study the fate of stents, particularly flow diverter stents placed in the abdominal aorta, in a rat model. This technique utilizes (caudal) tail artery access,1–5 thereby avoiding the need for surgical exposure of the femoral or carotid arteries and reducing procedural invasiveness,6 7 aligning with the principles of refinement and reduction in animal research.7 This approach may be particularly beneficial for studies requiring multiple or iterative vascular access. The use of ultrasound guidance further reduces costs and infrastructure requirements by eliminating the need for specialized angiography suites.8 This makes this technique accessible to a broader range of research settings, promoting wider adoption and collaboration in the field of endovascular research. A detailed demonstration of this method is provided in the accompanying educational video (video 1). Video 1 -Technical video describing the tail artery access and flow diverter deployment using ultrasound guidance.
Spousal Support and Physician Work-Life Integration and Burnout
O’Sullivan, Ciara C. , Jenkins, Sarah M. , Ruddy, Kathryn J. , Marshall, Ariela L. , Leep Hunderfund, Andrea N, Marshall, Ariela , Hunderfund, Andrea N. Leep , West, Colin P.

Mayo Clinic

JAMA Network Open | May 9, 2025 | Volume: 8 | Issue: 5 | Pages: e259507

10.1001/jamanetworkopen.2025.9507 | PMID 40343693 Get It

Importance Few studies have assessed whether factors outside the workplace, such as support from a spouse or partner, are associated with work-life integration (WLI) satisfaction and burnout among physicians. Evaluating such an association may help with developing novel strategies to address burnout and improve WLI satisfaction among this group. Objectives To compare spousal support among female and male physicians and explore associations of spousal support with WLI satisfaction and burnout. Design, Setting, and Participants This cross-sectional, multispecialty survey study was conducted among 661 faculty physicians employed at an academic medical center from March 26 to May 22, 2024. Main Outcomes and Measures Survey items measured spousal support (5 items), WLI satisfaction (1 item), and burnout (2 Maslach Burnout Inventory items). Associations of spousal support and gender with WLI and burnout were assessed using logistic regression analyses adjusting for age, race and ethnicity, weekly work hours, and weekly hours spent on household or childcare duties. Results Overall, 739 of 2103 faculty physicians (response rate, 35.1%) completed the survey, of whom 661 (89.4%) were currently married or partnered (359 of 661 men [54.3%]). In this subset, 322 of 351 male physicians (91.7%) and 276 of 298 of female physicians (92.6%) reported frequent career support (defined as often, most of the time, or always) over the last year from their spouse or partner. Physicians reporting high levels of career support from their spouse or partner had higher odds of WLI satisfaction (odds ratio [OR], 1.50 [95% CI, 1.22-1.86]; P < .001) and lower odds of burnout (OR, 0.73 [95% CI, 0.61-0.87]; P < .001), independent of gender and adjusted for age, race and ethnicity, weekly work hours, and weekly hours spent on household or childcare duties. Male physicians had higher odds of WLI satisfaction than female physicians (OR, 1.95 [95% CI, 1.32-2.90]; P < .001), even after adjusting for spousal career support and other covariates listed, whereas odds of burnout did not significantly differ by gender (OR, 0.84 [95% CI, 0.57-1.23]; P = .37). Conclusions and Relevance This study suggests that the level of career support from a spouse or partner is associated with WLI satisfaction and burnout among physicians, independent of gender. Future studies should explore whether interventions designed to enhance career support can improve WLI and well-being among physicians.
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Kumar, Shaji , Adekola, Kehinde , Anderson, Larry , Costello, Caitlin , D’Angelo, Christopher R. , Derman, Benjamin A. , Elsedawy, Noura, Godara, Amandeep , Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Robinson, Timothy, Valent, Jason , Varshavsky‐Yanovsky, Asya, Kovách, E, Holmberg, Leona , Anderson, Larry D. , Anderson, Larry D , Derman, Benjamin A , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Devarakonda, Srinivas , Kang, Yubin , Lee, Hans C. , Martin, Thomas G. , Rosenberg, Aaron , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Vogl, Dan T. , Kovach, Emily, Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2025 | Volume: 23 | Issue: 5 | Pages: 132-140

10.6004/jnccn.2025.0023 | PMID 40340857 Get It

The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as well as previously treated MM included in Version 1.2025 of the NCCN Guidelines for MM.
A Proposal for HPV-Associated Oropharyngeal Carcinoma in the Ninth Edition Clinical TNM Classification
Huang, Shao Hui, Su, Jie , Koyfman, Shlomo A. , Hoebers, Frank , Bahig, Houda , Yu, Eugene , Bartlett, Eric , Davis, Robin L. , Woody, N.M. , Nelson, Kristoff , Lavigne, Danny , Nguyen‐Tan, Phuc Félix, Létourneau‐Guillon, Laurent , Filion, Édith, Nagelschneider, Alex A. , Abel, Kathryn M. Van , Postma, Alida A. , Palm, Walter M. , Lydiatt, William M. , Patel, Snehal G. , Routman, David, Van Abel, Kathryn M , Huang, Shao Hui, Routman, David M. , Spreafico, Anna , Lee, Jonathan Wei Jie , Stock, Sarah Jane , Daniel, J. , Hoeben, Ann , Chua, Melvin L.K. , Xu, Wei , O'Sullivan, Brian P

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | May 8, 2025 | Volume: 151 | Issue: 7 | Pages: 655

10.1001/jamaoto.2025.0848 | PMID 40338536 Get It

Importance A subset of Union for International Cancer Control ( UICC )/ American Joint Committee on Cancer ( AJCC ) eighth edition TNM stage I and II human papillomavirus–positive oropharyngeal carcinoma has undesirable outcomes, which might have contributed to a lack of success in phase III deintensification trials. Refining clinical stage groups, especially in the overabundant cN1/stage I group, has become important for treatment selection. Objective To assess the prognostic importance of pretreatment lymph node (LN) characteristics to optimize case distribution and outcome homogeneity within the N classification system. Design, Setting, and Participants This is an international multi-institutional retrospective prognostic cohort study. Analysis of human papillomavirus–positive oropharyngeal carcinoma treated curatively from 4 institutions (International Collaboration of Oropharyngeal Cancer Network for N-Classification [ICON-N] dataset) provided a refined clinical staging proposal; an independent dataset (Centre Hospitalier de l’Université de Montréal [CHUM] dataset) validated the proposal. Neuroradiologists reviewed pretreatment computed tomography and/or magnetic resonance imaging for nodal features, including presence or absence of abnormal LN(s), retropharyngeal LN, laterality, number of abnormal LN, and imaging-detected extranodal extension (iENE). Data were collected from February to May 2023, and data were analyzed from June to July 2023. Exposures Definitive chemoradiotherapy/radiotherapy or definitive surgery with or without postoperative chemoradiotherapy/radiotherapy. Main Outcomes and Measures The primary end point was overall survival. A Cox proportional hazards multivariable model was used to estimate adjusted hazard ratios (AHRs) and to derive an optimal clinical TNM stage classification (AHR-stage schema) incorporating the strongest prognostic nodal features within the UICC/AJCC eighth edition TNM framework after confirming the prognostication of iENE status. The performance (according to overall normalized scores and ranking) of the AHR-stage schema against the current UICC/AJCC eighth edition TNM staging system was evaluated for hazard consistency, hazard discrimination, prognostic importance, and sample size balance. Validation was performed in the CHUM dataset. Results The ICON-N dataset comprised 2053 patients, including 1898 (92.5%) with cN-positive disease and 155 (7.5%) with cN0 disease; a total of 298 (14.5%) were female, and the mean (SD) age was 60.6 (9.3) years. iENE-positive disease was identified in 710 of 1898 patients with cN-positive disease (37.4%). The median (range) follow-up was 5.1 (0.1-14.7) years. iENE was the strongest prognostic nodal feature in multivariable analysis; the AHR for iENE-positive vs iENE-positive disease was 2.43 (95% CI, 1.96-3.03) in the ICON-N dataset and 2.04 (95% CI, 1.28-3.23) in the CHUM dataset (n = 451). Reclassifying iENE-positive cases 1 stratum higher for N categorization without altering iENE-negative cases yielded an AHR-stage schema that outperformed the current TNM staging system in disease-free and overall survival with a lower (ie, better) overall normalized score (2 vs 3). Conclusions and Relevance In this study, reclassifying each N category 1 stratum higher for iENE-positive disease resulted in better disease-free and overall survival. The proposed new classification outperformed the currently TNM staging system in risk stratification and may facilitate future clinical trial design, outcomes research, and patient care.
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma
Cheville, John C. , Kopp, Karla, Torell, Nate R, Lavoie, Roxane R. , Farrell, Ava, Jaszewski, Brandy L., Jenkins, Sarah M. , Dasari, Surendra , Menon, Santosh, Whaley, Rumeal D. , Boorjian, Stephen A. , Pagliaro, Lance C. , Gupta, Sounak , Lucien, Fabrice , Kopp, Karla J, Smith, Carin Y , Tekin, Burak , Lucien, Fabrice , McCarthy, Michael, Dong, Haidong , Smith, Carin Y. , Erickson, Lori A, Guo, Ruifeng

Mayo Clinic

American Journal of Clinical Pathology | May 6, 2025 | Volume: 163 | Issue: 6 | Pages: 898-908

10.1093/ajcp/aqaf022 | PMID 40327767 Get It

Abstract Objectives We aimed to assess the expression of biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma (pSCC). Methods Our archive was queried for patients who had a penectomy for pSCC between 2000 and 2022. Primary tumors were immunostained for B7-H3 and NKG7, while metastatic specimens were immunostained for TROP2 and nectin-4. Expression of PD-L1, TROP2, and nectin-4 in primary tumors was previously characterized. H-scores (0-300) were used to quantify expression. Associations between biomarkers, tumor-infiltrating lymphocytes (TILs), and clinicopathologic and outcome parameters were evaluated. Results For both TROP2 and nectin-4, H-scores within the lymph node metastases were higher compared to those within the primary tumors (mean, 264.5 vs 244.8, P = .0003; mean, 170.6 vs 146.7, P = .05, respectively; 33 paired specimens). For B7-H3 (n = 107), 32.7% of the primary tumors had an H-score of more than 0. In 34.8% of the cases, NKG7 expression was observed in 25% to 50% of the TILs. A significant association was noted between TIL density, B7-H3, NKG7, and PD-L1 expression. Conclusions Therapeutic strategies targeting TROP2 and nectin-4 hold promise for patients with advanced pSCC. The potential of PD-L1, B7-H3, and NKG7 for predicting response to immunomodulatory treatment warrants further research.